Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to
its success for hematological malignancies in clinical studies leading to the US Food and …

Five-year survival rates for non–small cell lung cancer (NSCLC) range from 14% to 49% for
stage I to stage IIIA disease, and are< 5% for stage IIIB/IV disease. Improvements have been …

Radiation is an important component of cancer treatment with more than half of all patients
receive radiotherapy during their cancer experience. While the impact of radiation on tumour …

The use of immunomodulation to treat malignancies has seen a recent explosion in interest.
The therapeutic appeal of these treatments is far reaching, and many new applications …

Radiotherapy is a pivotal component in the curative treatment of patients with localised
cancer and isolated metastasis, as well as being used as a palliative strategy for patients …

Despite advances in our understanding of the underlying molecular drivers of sarcomas, few
treatments are available with proven benefit for advanced metastatic sarcomas …

Treatment with ionizing radiation (IR) remains the cornerstone of therapy for multiple cancer
types, including disseminated and aggressive diseases in the palliative setting …

A large number of liver transplants have been performed for hepatocellular carcinoma
(HCC), and recurrence is increasingly encountered. The recurrence of HCC after liver …

Solid cancers are able to escape immune surveillance and are resistant to current treatment
in immunotherapy. Recent evidence indicates the critical role of the stimulator of interferon …

Cancer cells subjected to ionizing radiation may release signals which can influence nearby
non-irradiated cells, termed bystander effects. The transmission of bystander effects among …